Keyphrases
Single Institution
100%
Phase II Study
100%
Multiple Myeloma
100%
Bortezomib
100%
Maintenance Therapy
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Natural Killer Cells
20%
Overall Response Rate
20%
Pretransplant
20%
Overall Survival
20%
CD56+
20%
CD8+
20%
No Adverse Effect
20%
Kaplan-Meier Estimator
20%
Partial Remission
20%
Stem Cell Engraftment
20%
Induction Therapy
20%
Granulocyte Colony-stimulating Factor (G-CSF)
20%
2-cycles
20%
Disease-free Survival
20%
Cytotoxic T Cells
20%
Varicella Zoster
20%
High-dose Melphalan
20%
Viral Reactivation
20%
Stem Cell Mobilization
20%
Immunology and Microbiology
Multiple Myeloma
100%
Natural Killer Cell
50%
CD8
50%
Drug Megadose
50%
Stem Cell
50%
Overall Survival
50%
Varicella Zoster Virus
50%
Disease Free Survival
50%
Engraftment
50%
Granulocyte Colony-Stimulating Factor
50%
Peripheral Blood Lymphocyte
50%
Cytotoxic T Cell
50%
Pharmacology, Toxicology and Pharmaceutical Science
Bortezomib
100%
Multiple Myeloma
100%
Overall Survival
20%
Remission
20%
CD8 Antigen
20%
Varicella Zoster Virus
20%
Disease Free Survival
20%
Melphalan
20%
Granulocyte Colony Stimulating Factor
20%